Background:

North American Adult T-cell leukemia/lymphoma (NA-ATLL) is a rare and aggressive malignancy of CD4+ T-cells associated with HTLV-I infection. Despite varied treatment approaches, acute ATLL has an overall survival of less than one year. Zidovudine (AZT) with Interferon-alpha has been the backbone of acute ATLL treatment for the past three decades. While AZT-monotherapy was the first treatment to show benefit for HIV infection, combination therapy, such as the fixed-dose combination tablet Bictegravir-Emtricitabine-Tenofovir alafenamide (Biktarvy) has superior outcomes and has become standard of care for HIV treatment. There is preclinical evidence that these agents have activity against HTLV-I and it was proposed to deploy them in ATLL. Thus, for the first time to our knowledge, we sought to determine safety and efficacy of PEG-IFN alpha and Biktarvy in our ATLL cohort.

Methods:

Seven patients with a range of aggressive Shimoyama phenotypes were treated: one acute, six lymphomatous (two relapsed) and one chronic unfavorable. The regimen consisted of weekly subcutaneous Peginterferon alpha-2a 180 mcg and Biktarvy daily. This backbone was combined with Venetoclax in one patient and mogamulizumab in another. We measured overall response rate via imaging, virologic response, adverse events, and mutational profile. Virologic response was evaluated by measuring HTLV-I viral load (copies/ml) before and during treatment.

Results:

Overall response rate was 100% with confirmed imaging resolution in six subjects. One patient lacked imaging confirmation but had dramatic resolution of skin lesions and lymphadenopathy. All patients remain alive, with median survival of 279 days (range 95-396 days) versus 33 days (range 3-92 days) in historic controls. This survival benefit is significant with a p-value <0.00011 via log rank test. We observed a sustained decrease in mean viral load of 91.17% (range 68% to 100%) with a one-sided p-value of 0.007813 via paired-Wilcoxon test. The circulating component of ATLL cells was eliminated in 6 out of 7 patients, 3 prior to transplant and 3 post transplant. The observed adverse effects included: grade 1-2 fatigue and cytopenias in five out of seven patients (71.4%), G4 neutropenia in one patient (14.3%) and G4 febrile neutropenia with sepsis in one patient (14.3%). Five patients continued therapy with no interruptions, one stopped due to relapse, and another due to severe cytopenia/sepsis.

Conclusions:

All cases in this study achieved a sustained complete remission, significantly superior to prior historical controls. Most observed toxicities were tolerable. There was one grade 4 adverse effect with severe pancytopenia and sepsis attributed to Venetoclax. We conclude that PEG-IFN and Biktarvy are safe and effective in patients with ATLL, particularly showing positive outcomes in multiply relapsed patients, a group previously with limited options and extremely poor outcomes. We propose integrating Biktarvy and PEG-IFN as part of induction or maintenance strategies in ATLL, possibly in combination with other agents. A prospective clinical trial is being designed to evaluate the effect of PEG-IFN and Biktarvy in a larger standardized patient cohort.

Disclosures

Shastri:Kymera: Research Funding; Jassen: Consultancy; NACE & PeerView: Honoraria; Gilead, Rigel, Kymera: Consultancy; Ryvu therapeutics: Research Funding; Geron: Speakers Bureau. Konopleva:F. Hoffmann-LaRoche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Other: clinical trials; Sanofi Aventis: Consultancy, Other: clinical trials, Research Funding; Menarini Group: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: clinical trials, Research Funding; ImmunoGen: Research Funding; Rafael Pharmaceutical: Research Funding; Dark Blue Therapeutics: Membership on an entity's Board of Directors or advisory committees; Legend Biotech: Consultancy; Precision Biosciences: Research Funding; Pfizer: Other: clinical trials; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sellas: Consultancy; Cellectis: Other: Clinical Trials; Immune Oncology: Membership on an entity's Board of Directors or advisory committees; Reata Pharmaceutical: Other: IP; Redona: Consultancy; MEI Pharma: Consultancy, Research Funding; Vincerx: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: clinical trials, Research Funding; Boehringer: Consultancy; Bakx Therapeutics: Membership on an entity's Board of Directors or advisory committees; Auxenion GmbH: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Other: clinical trials, Research Funding; Allogene: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: clinical trials, Research Funding. Verma:Clinstreet: Current equity holder in private company; Bioconvergent health: Current equity holder in private company; Prelude: Research Funding; Bristol Myers Squib: Research Funding; Curis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Halia: Research Funding; Calico: Membership on an entity's Board of Directors or advisory committees; Stelexis: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees. Janakiram:LEGEND: Honoraria, Research Funding; FATE THERAPEUTICS: Research Funding; JANNSEN: Honoraria, Research Funding; BMS: Honoraria, Research Funding.

Off Label Disclosure:

This paper reports the use of Bictegravir-Emtricitabine-Tenofovir alafenamide 50mg-200mg-25mg (Biktarvy) in Adult T-cell leukemia/lymphoma (ATLL) patients. Biktarvy is FDA approved for HIV patients. We report its use here in place of Zidovudine, a previous antiviral studied in ATLL populations.

This content is only available as a PDF.
2024
Sign in via your Institution